Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Primary Healthcare Services01:30

Primary Healthcare Services

Primary care promotes wellness and prevents disease. This care includes health promotion, education, protection (such as immunizations), early disease screening, and environmental considerations. Settings providing this type of healthcare include physician offices, public health clinics, school nursing, and community health nursing.
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical implications of the ACCORD trial.

The Journal of clinical endocrinology and metabolism·2011
Same author

A medical emancipation proclamation.

Archives of internal medicine·2000
Same author

Implications of the United Kingdom prospective diabetes study for patients with obesity and type 2 diabetes.

Obesity research·2000
Same author

Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial.

Diabetes·1999
Same author

For aggressive preventive management of type 2 diabetes. What is the evidence and is it enough?

The Journal of family practice·1998
Same author

United Kingdom prospective diabetes study results are in.

The Journal of family practice·1998

Related Experiment Video

Updated: Jul 2, 2026

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

The UKPDS and its global impact.

S Genuth1

  • 1Department of Medicine, Case Western Reserve University, Cleveland, OH, USA. smg15@case.edu

Diabetic Medicine : a Journal of the British Diabetic Association
|September 9, 2008
PubMed
Summary

The United Kingdom Prospective Diabetes Study (UKPDS) significantly impacted global diabetes care. It established intensive glycemic control targets, influencing treatment guidelines and improving patient outcomes worldwide.

Area of Science:

  • Endocrinology
  • Public Health
  • Clinical Trials

Background:

  • The United Kingdom Prospective Diabetes Study (UKPDS) provided crucial data on type 2 diabetes management.
  • Previous research, like the Diabetes Control and Complications Trial (DCCT), linked microvascular complications to blood glucose control.

Purpose of the Study:

  • To review the global impact of the UKPDS on diabetes healthcare since 1998.
  • To assess the influence of UKPDS findings on clinical practice and treatment guidelines worldwide.

Main Methods:

  • Review of major UKPDS publications.
  • Surveys sent to international diabetes associations regarding HbA1c trends.
  • Analysis of data from a major US laboratory on HbA1c levels.

More Related Videos

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
06:16

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

Measuring Sub-23 Nanometer Real Driving Particle Number Emissions Using the Portable DownToTen Sampling System
08:59

Measuring Sub-23 Nanometer Real Driving Particle Number Emissions Using the Portable DownToTen Sampling System

Published on: May 22, 2020

Related Experiment Videos

Last Updated: Jul 2, 2026

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
06:16

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

Measuring Sub-23 Nanometer Real Driving Particle Number Emissions Using the Portable DownToTen Sampling System
08:59

Measuring Sub-23 Nanometer Real Driving Particle Number Emissions Using the Portable DownToTen Sampling System

Published on: May 22, 2020

Main Results:

  • UKPDS reinforced the link between intensive glycemic control and reduced microvascular complications in type 2 diabetes.
  • Established a target HbA1c of <7.0% for intensive glycemic treatment, influencing medical education.
  • Supported metformin as a first-line therapy and stimulated new hypoglycemic drug development.
  • Observed a global trend towards lower HbA1c levels post-UKPDS publication.
  • Demonstrated cost-effectiveness of intensive UKPDS treatment strategies.

Conclusions:

  • The UKPDS is a landmark study that has shaped worldwide standards of care for type 2 diabetes.
  • Its findings continue to influence treatment guidelines and clinical decision-making globally.
  • The study highlighted the benefits of early and intensive management in type 2 diabetes.